Vera Therapeutics (VERA) Total Liabilities (2020 - 2026)

Vera Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $122.0 million for Q1 2026.

• Quarterly Total Liabilities rose 62.36% year-over-year to $122.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.0 million (up 62.36% YoY) and the FY2025 annual result came in at $130.2 million, up 65.82% from the prior year.
• Total Liabilities was $122.0 million for Q1 2026 at Vera Therapeutics, down from $130.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $130.2 million in Q4 2025 and bottomed at $25.7 million in Q3 2022.
• A 5-year average of $71.8 million and a median of $69.4 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 448.95% — and 2024, when it advanced 6.32%.
• Vera Therapeutics' Total Liabilities stood at $54.5 million in 2022, then soared by 35.46% to $73.9 million in 2023, then grew by 6.32% to $78.5 million in 2024, then surged by 65.82% to $130.2 million in 2025, then decreased by 6.27% to $122.0 million in 2026.
• Business Quant data shows VERA's Total Liabilities at $122.0 million in Q1 2026, $130.2 million in Q4 2025, and $118.6 million in Q3 2025.